Orally disintegrating selegiline for the treatment of Parkinson's disease

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.9, Iss.16, 2008-11, pp. : 2881-2891

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease

By Tábi Tamás Szökő Éva Vécsei László Magyar Kálmán

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 5, 2013-05 ,pp. : 629-636

Informa Healthcare

Access to resources Recommend Favorite

Safety of Selegiline (Deprenyl) in the Treatment of Parkinson's Disease

By Heinonen E.H.

Drug Safety, Vol. 19, Iss. 1, 1998-07 ,pp. : 11-22

Adis International

Access to resources Recommend Favorite

Acute Treatment of Migraine with Zolmitriptan 5mg Orally Disintegrating Tablet

By Egilius L.H. Spierings Alan M. Rapoport

CNS Drugs, Vol. 18, Iss. 15, 2004-01 ,pp. : 1133-1141

Adis International

Access to resources Recommend Favorite

Acceptability of Lansoprazole Orally Disintegrating Tablets in Patients with Gastro-Oesophageal Reflux Disease: ACEPTO Study

By de Argila Carlos Martín

Clinical Drug Investigation, Vol. 27, Iss. 11, 2007-01 ,pp. : 765-770

Adis International

Access to resources Recommend Favorite

Fed and Fasted Administration of a Novel Extended‐Release Methylphenidate Orally Disintegrating Tablet Formulation for the Treatment of ADHD

Clinical Pharmacology In Drug Development, Vol. 7, Iss. 2, 2018-02 ,pp. : 160-167

John Wiley & Sons Inc

Access to resources Recommend Favorite